CSPC Pharmaceutical Group Ltd. has obtained clearance by China’s National Medical Products Administration (NMPA) to conduct clinical trials in China with SYS-6023 for advanced solid tumors.
Development and optimization of novel oral selective hematopoietic progenitor kinase 1 (HPK1) inhibitors for immuno-oncology (IO) treatment were reported by scientists from Astrazeneca plc in two presentations during the ACS meeting this week.
Iambic Therapeutics Inc. has described HER2 (erbB2) and HER2 (exon 20 insertion [Ex20Ins] [Ala775_Gly776insTyrValMetAla]) mutant inhibitors reported to be useful for the treatment of non-small-cell lung cancer (NSCLC).
Shanghai Yingli Pharmaceutical Co. Ltd. has identified dual-acting phosphatidylinositol 3-kinase (PI3K) and histone deacetylase (HDAC) inhibitors reported to be useful for the treatment of cancer.
Sanofi SA has synthesized compounds acting as selective estrogen receptor degradation inducers (SERDs) reported to be useful for the treatment of cancer, endometriosis, osteoporosis, benign prostatic hyperplasia and inflammatory disorders.
Scientists at Jiangsu Hengrui Medicine Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have disclosed poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of cancer.
Redx Pharma plc has described discoidin domain-containing receptor 1 (DDR1) and/or discoidin domain-containing receptor 2 (DDR2) inhibitors reported to be useful for the treatment of cardiovascular, renal, inflammatory disorders, liver diseases, fibrosis, transplant rejection and cancer.
Jacobio Pharmaceuticals Co. Ltd. has divulged cellular tumor antigen p53 (TP53) (Y220C mutant) stabilizers reported to be useful for the treatment of cancer.
Erasca Inc. has disclosed proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety covalently linked to a GTPase KRAS G12D mutant targeting moiety through a linker reported to be useful for the treatment of cancer.
RSS
